期刊
JOURNAL OF DERMATOLOGY
卷 -, 期 -, 页码 -出版社
WILEY
DOI: 10.1111/1346-8138.17021
关键词
biologics; dupilumab; immunoglobulin E; Kimura's disease; omalizumab
类别
Kimura's disease is a chronic inflammatory disease with limited treatment options. This study found that biologics such as omalizumab could serve as an alternative treatment strategy for Kimura's disease.
Kimura's disease (KD) is a chronic inflammatory disease characterized by painless subcutaneous head and neck swelling, eosinophilia, and elevated serum immunoglobulin (Ig) E levels. There are various therapies, including surgery, radiation, systemic steroids, and immune suppressants, but their efficacy remains moderate due to the high recurrence rate. Biologics, like monoclonal antibodies, have shown tremendous effectiveness for chronic inflammatory diseases. Omalizumab is a monoclonal antibody against IgE and has not been approved for KD so far. We describe two refractory KD cases that responded to a small dose of steroids plus omalizumab. Additionally, we reviewed another 13 KD cases that were treated with biologics, including omalizumab, rituximab, dupilumab, and mepolizumab. The results indicate that biologics provide an alternative treatment strategy for KD.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据